The sales of cardiac glycosides in Spain have exhibited a continuous declining trend from 2013 to 2023, starting at 3.1 million euros and decreasing to 1.4 million euros. The year-on-year percentage variation highlights significant declines in sales, with notable drops of -11.11% in 2022 and -12.5% in 2023. The Compound Annual Growth Rate (CAGR) over the last five years demonstrates an average annual decrease of -9.45%, indicative of a persistent downward trend.
Forecasts for 2024 through 2028 predict this downward trajectory to continue, with sales expected to fall to 0.6 million euros by 2028. The forecasted five-year CAGR from 2023 to 2028 is -14.33%, reflecting a substantial annual contraction. Overall, a substantial 53.85% decline in sales is projected over this period.
Future trends to watch for include potential market shifts due to emerging alternatives to cardiac glycosides, changes in healthcare policies, and advancements in medical treatments that could further impact the demand for traditional cardiac glycosides in Spain.
